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In assuming the role of Editor-in-Chief for the Journal of
Molecular Diagnostics, I am filled with humility, trepida-
tion, and excitement. It is humbling to follow in Karen
Kaul’s footsteps. As the inaugural editor of the JMD,
she exceeded the goals that the leaders of the Asso-
ciation for Molecular Pathology set forth—“to give
equal value to new technology and new discoveries, to
provide careful validation and comparison of clinical
assays, and to promote our growing expertise, as well
as that of this fledgling organization, AMP.”1 Karen and
her editorial team developed the JMD into a journal that
remains the first source for definitive information on
how to bring molecular diagnosis into clinical practice.
It is this success that drives me forward as I take on this
challenge.
The excitement that comes with the opportunity to
build on this great legacy is accompanied by trepida-
tion that arises from three sources. First, the role of the
molecular pathologist within the health professional
community is constantly in flux. Our colleagues in the
corporate world are developing impressive products
that effectively bring certain elements of molecular di-
agnostics practice into the hands of generalists who, at
least presently, are not reading the JMD. The changing
scope of practice, together with the development of
new technologies designed to rapidly characterize the
genome, transcriptome, and proteome, challenges the
JMD editorial team to constantly reexamine content
and scope to assure that published papers enable our
readers to effectively serve patients, health profession-
als, and the scientific community. Second, the forms
and functions of scientific journals are changing. Al-
though those of us “of a certain age” are familiar with
reading bound collections of paper, libraries are dis-
pensing with them for lack of space, and some readers
prefer instead to use a computer, for reasons ranging
from personal convenience to environmental concerns.
More importantly, traditional journals, including most
electronic versions, do not take full advantage of the
Internet’s capabilities to connect different documents
and concepts, to provide video illustrations to commu-
nicate more effectively than print, or to distribute audio
formats that are more convenient and portable for
some “readers.” Finally, the editorial team, including
the sponsoring societies, must remain as aware of
opportunities to use evolving publishing models as
they are diligent in bringing forth scientific communi-
cations of the highest quality. These tasks are beyond
my personal abilities, so I am thankful that Barbara
Zehnbauer has agreed to serve as Senior Associate
Editor, that Managing Editor Audra Cox and the edito-
rial office are continuing their exceptional work with the
JMD, and that the Associate Editors, Editorial Board
members, and the Joint Journal Oversight Committee
will maintain their constant and careful attention to
the JMD.
The editorial team stands strongly committed to
meeting these challenges while increasing the impor-
tance, readership, and visibility of the JMD. To achieve
these goals, we will broaden the JMD content to in-
clude papers reflecting an earlier stage in the transla-
tional pipeline. We wish to reach a broader audience
that includes scientists who are developing tools with
an impact on diagnosticians who practice molecular
pathology “in the trenches.” In addition to articles that
have been within the traditional scope of the JMD, we
will encourage those that define technological innova-
tion (both physical and informational), including cross-
over technologies such as molecular imaging. The ed-
itorial team will also solicit papers that firmly establish
the clinical validity and utility of molecular diagnostic
methods, including clinical trials and epidemiological
investigations. Over time, we will expand the Editorial
Board to encourage submissions and facilitate expert
review in these areas. We will also actively solicit top-
ical reviews intended to bring advances in molecular
diagnostics and diagnostic technology into practical
scientific and clinical context. Authors who are inter-
ested in submitting a review to the JMD should contact
the journal office before preparation to assure that it
advances the JMD’s goals.
We will strive to serve our authors with the same care
that we serve our readers. Our commitment to bringing
high-quality research to our readers as quickly as pos-
sible will be accompanied by efforts to reach a final
editorial decision on all submitted manuscripts within
28 days, while assuring that scientific review is helpful
to authors. For this we will depend heavily on our
Editors, Editorial Board members, and ad hoc review-
ers to provide timely, constructive reviews. Further, for
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contributions that represent exceptionally important
advances, we will strive to accelerate not only review
but also publication to assure maximum visibility for
authors and rapid availability to readers.
Although the JMD’s editorial team is strong, it alone
cannot continue the tradition of excellence that the
JMD has established. We encourage the JMD’s read-
ers and authors to share with us their insights on the
JMD’s successes, missteps, and future directions.
Together we can effectively build on the firm founda-
tion of the last 11 years to make a great journal even
better.
Timothy J. O’Leary, M.D., Ph.D.
Editor-in-Chief
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